Close Menu

NEW YORK (GenomeWeb) – RTI and Asuragen today announced a collaboration to perform high-throughput screening testing for fragile X syndrome in newborns.

Using Asuragen's technology, screening will be conducted in North Carolina's Early Check study, a free screening study to identify children with rare health conditions before symptoms appear and assess the value of benefits of early intervention. With a mother's consent, Early Check reuses the same blood sample taken for regular newborn screening to test for additional conditions, such as fragile X syndrome.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.